Inovio Pharmaceuticals (NASDAQ:INO) Given Overweight Rating at Piper Sandler

Piper Sandler restated their overweight rating on shares of Inovio Pharmaceuticals (NASDAQ:INO) in a research report released on Wednesday,Benzinga reports. They currently have a $6.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $8.00.

A number of other brokerages also recently issued reports on INO. Jefferies Financial Group restated a “buy” rating and set a $8.00 price objective (up from $3.00) on shares of Inovio Pharmaceuticals in a research report on Friday, November 6th. HC Wainwright set a $5.00 price objective on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, November 2nd. Weiss Ratings cut Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 13th. Wall Street Zen raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Zacks Research downgraded shares of Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 12th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.33.

Inovio Pharmaceuticals Stock Up 1.7%

Shares of NASDAQ:INO opened at $1.48 on Wednesday. Inovio Pharmaceuticals has a 12-month low of $0.56 and a 12-month high of $2.72. The business has a fifty day simple moving average of $1.18 and a 200 day simple moving average of $1.27.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.29). The business had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $2.27 million. On average, analysts forecast that Inovio Pharmaceuticals will post -0.74 EPS for the current fiscal year.

Institutional Trading of Inovio Pharmaceuticals

Large investors have recently bought and sold shares of the business. Eversept Partners LP acquired a new position in shares of Inovio Pharmaceuticals in the 1st quarter valued at about $1,802,000. Renaissance Technologies LLC boosted its position in shares of Inovio Pharmaceuticals by 16.4% during the 1st quarter. Renaissance Technologies LLC now owns 643,777 shares of the biopharmaceutical company’s stock valued at $1,120,000 after purchasing an additional 90,613 shares in the last quarter. Squarepoint Ops LLC boosted its position in shares of Inovio Pharmaceuticals by 46.5% during the 2nd quarter. Squarepoint Ops LLC now owns 36,391 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 11,554 shares in the last quarter. Engineers Gate Manager LP bought a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter valued at about $37,000. Finally, Prime Capital Investment Advisors LLC grew its stake in Inovio Pharmaceuticals by 312.4% during the third quarter. Prime Capital Investment Advisors LLC now owns 70,636 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 53,510 shares during the period. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals News Roundup

Investors following INO have been watching these news items:

• Positive Sentiment: INOVIO said VOCERYQ received FDA accelerated approval to reduce surgery frequency in adults with recurrent respiratory papillomatosis. The company expects the treatment to be available to order and ship about 60 days after approval, with a full commercial launch in Q1 2027. The approval also marks the first FDA-approved DNA medicine, potentially validating INOVIO’s platform. INOVIO Q3 results and business highlights
• Neutral Sentiment: Piper Sandler maintained its “overweight” rating but cut its price target to $6 from $8. The lower target is a negative revision, though it remains well above the $1.48 reference price in the provided background. Piper Sandler rating
• Neutral Sentiment: INOVIO plans to participate in upcoming investor conferences, which may give management a forum to discuss its commercial plans but is not itself a new business milestone. Investor conferences announcement

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company’s platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells. Inovio’s product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases.